Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509210 · ClinicalTrials.gov registry record · Phase 1
Study of Telaprevir in Subjects With Hepatic Impairment
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00509210 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated.
The verdict
NCT00509210, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment.
Interventions
- DRUG telaprevir (VX-950)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2007-09 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00509210
The ClinicalTrials.gov registry entry for NCT00509210 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which telaprevir (VX-950) is the first listed.
NCT00509210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00509210 about?
NCT00509210 is a clinical study titled "Study of Telaprevir in Subjects With Hepatic Impairment". The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment.
What is the current status of trial NCT00509210?
This trial is currently completed. It is a Phase 1 study. The study started on 2007-09. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00509210?
The interventions under investigation include: telaprevir (VX-950) (DRUG).
Who is sponsoring clinical trial NCT00509210?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.